Background-Vascular endothelial growth factor (VEGF) is a prime mediator of
INTRODUCTION
Nine of 19 studies based on multivariate survival analysis identified high VEGF expression as an indicator of poor prognosis, and the remaining 10 showed no statistically significant effect of VEGF high expression on survival.
Quality assessment based on REMARK guidelines was performed on all 31 studies included for systematic review. The mean number of study quality items reported was 11 out of a possible 18, and there was no statistical difference between studies that assessed the outcome with univariate survival analysis(n=12) or with multivariate survival analysis(n=19), with mean items being 10.7 and 11.2, respectively (p=0.297).
All studies reported details of the assay type, manufacturer, cutpoint determination, clinical endpoint and univariate estimation. More than 80% reported details of population source, sample handling, conventional risk factors, and multivariate estimation. Of note, 17 studies attempted to control for other important prognostic factors that may have confounded the association of high VEGF with survival. Three studies referred to validation of outcome but no studies referred to rational sample size and missing value.
The results of the meta-analysis are reported in Table 3 and in Figure 2 . For all studies, with one exception with HR=1 (95%CI 1.00-1.00) (73), there did not appear to be any major qualitative evidence for heterogeneity between HRs, as assessed by inspection of the Forrest plot ( Figure 3 ). For studies evaluating VEGF levels in ESCC and EC, the combined HRs were 1.81 (95%CI 1.57-2.10) and 2.24 (95%CI 1.41-3.55), respectively, and there was no evidence for heterogeneity within the two groups. The pooled HR estimate for survival in the 25 studies using IHC was 1.72 (95%CI 1.47-2.02), with no evidence for heterogeneity between studies. However, when we limited the analysis to the 14 studies (n=1064) with a higher proportion of disease stage Ⅲ+Ⅳ (more than 50%), the combined HR was 1. Visual assessment of funnel plots provided no evidence of overt publication bias for the studies (Figure 3 ). Formal evaluation using Egger's test also failed to reveal evidence for significant publication bias (P=0.543).
DISCUSSION
In this meta-analysis we found high VEGF expression in esophageal cancers to be associated with an approximate 80% higher risk of death from the disease. Our current finding is in agreement with recent meta-analysis reports on VEGF expression in colorectal cancer, oral carcinoma, and gastric carcinoma. (76-78)
Quality assessment tools are being developed for prognostic studies to help identify study bias and causes of heterogeneity when performing meta-analysis. We chose to use the REMARK guidelines, which provide a useful start for assessing tumor prognostic markers (15 
